Inquiry backs expansion of GLP-1 RA eligibility

Government urged to make Glucagon-like Peptide-1 receptor agonists (GLP-1 RAs) available to more patients  Steps to improve access to GLP-1 RAs for high-risk patients are among 23 recommendations in the Parliamentary Standing Committee on Health, Aged Care and Sport’s inquiry into diabetes.   The committee noted that GLP-1 RAs, including semaglutide (Ozempic) and dulaglutide (Trulicity),

This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.

Forgot Password?Why do I need to login & stay in?

Previous Guild launches 8CPA calculator
Next EBOS lifts stake in MedAdvisor